319460-85-0 Axitinib AKSci J11463
Loading Please Wait...
  J11463    AKSci Reference Standard
, 98% (HPLC), powder

CAS Number:319460-85-0
MDL Number:MFCD09837898
Min. Purity Spec:98% (HPLC), powder
Spectra:NMR, HPLC
Physical Form:White to tan powder
Melting Point:211-214°C
Long-Term Storage:Store long-term at -20°C
Not hazardous material

Solubility:DMSO: 42mg/mL; H2O: <1mg/mL; EtOH: <1mg/mL
Application(s):Inhibits multiple targets, including VEGFR-1, VEGFR-2, VEGFR-3, platelet derived growth factor recep
Form:Free base


 The vascular endothelial growth factor receptor (VEGFR), a signal protein, is responsible for the origination and progression of various tumours. VEGFR-1 plays a major role in the growth of new blood vessels from the old blood vessels (angiogenesis) and tumour growth. VEGFR-2 plays an important role in the endothelial cell proliferation, migration and survival, and angiogenesis. VEGFR-3 is involved in the formation of new lymphatic vessels from already existing lymphatic vessels (lymphangiogenesis). Axitinib has the ability to inhibit VEGFR-1, 2 and 3 selectively. It binds to the receptors of the VEGF and inhibits it, thereby preventing the formation of new blood vessels.

[1]Hu-Lowe et al (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2 and 3. Clin.Cancer Res. 14 7272. PMID: 19010843.
[2] Ma and Waxman (2008) Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol.Cancer Ther. 7 79. PMID: 18202011.
[3] Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL, Partridge SC, Henry RG, Shalinsky DR, Hu-Lowe D, Park JW, McShane TM, Lu Y, Brasch RC, Hylton NM. (2007) AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 25(3):319-27
[4] Rini B, Rixe O, Bukowski R, Michaelson MD, Wilding G, Hudes G, Bolte O, Steinfeldt H, Reich SD, Motzer R. (2005) AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). ASCO Proceedings Abstract 4509.



Signal Word

Hazard Statements
H302; H410

Precautionary Statements
P264; P270; P273; P301+P312; P330; P391; P501

Current as of April 23, 2021

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.

Download SDS

For research use only. Not for diagnostic or therapeutic use. Not for human use. AK Scientific, Inc. does not sell to individuals. If you are a first-time customer, please email for review at least two official business documents issued by your local jurisdiction, state/province, or country.


 APIs and Bioactives > Protein Kinase Inhibitors